臺北醫學大學泌尿腎臟研究中心

Medicine & Life Sciences

1. Chronic Renal Insufficiency 100%
2. Taiwan 81%
3. Renal Dialysis 71%
4. Kidney 68%
5. Cohort Studies 41%
6. Dialysis 34%
7. Prostatic Neoplasms 34%
8. Chronic Kidney Failure 33%
9. Meta-Analysis 32%
10. Apoptosis 32%
11. Population 29%
12. Mortality 29%
13. Autophagy 29%
14. Reactive Oxygen Species 27%
15. Therapeutics 23%
16. Confidence Intervals 22%
17. Neoplasms 21%
18. Systematic Reviews 21%
19. Serum 20%
20. Heme Oxygenase-1 20%
21. Acute Kidney Injury 19%
22. Endothelin-1 19%
23. Prostate 19%
24. Odds Ratio 19%
25. Wounds and Injuries 18%
26. Arsenic 17%
27. Genes 17%
28. Chronic Obstructive Pulmonary Disease 16%
29. Peroxisome Proliferator-Activated Receptors 16%
30. Proteins 16%
31. urotensin II 16%
32. Inflammation 16%
33. Down-Regulation 16%
34. Lung Neoplasms 15%
35. Congenital bilateral aplasia of vas deferens 15%
36. Indican 15%
37. Randomized Controlled Trials 14%
38. Nanoparticles 14%
39. Carcinoma 14%
40. Peritoneal Dialysis 14%
41. Urinary Bladder Neoplasms 14%
42. Human Umbilical Vein Endothelial Cells 13%
43. ErbB Receptors 13%
44. Endothelial Cells 13%
45. Heart Failure 13%
46. Triple Negative Breast Neoplasms 13%
47. Doxorubicin 12%
48. Extracellular Signal-Regulated MAP Kinases 12%
49. Databases 12%
50. Gene Expression 12%
51. Hypertension 12%
52. Hospitalization 11%
53. Fibrosis 11%
54. Vitamin D 11%
55. Metabolic Syndrome 11%
56. Up-Regulation 11%
57. Angiotensin II 11%
58. Adenocarcinoma of Lung 11%
59. Parathyroid Hormone 11%
60. Androgen Receptors 11%
61. Biomarkers 11%
62. Lipopolysaccharides 11%
63. Interleukin-8 11%
64. Glomerular Filtration Rate 11%
65. Genotype 11%
66. Androgens 11%
67. Membranous Glomerulonephritis 11%
68. Hydroxymethylglutaryl-CoA Reductase Inhibitors 11%
69. In Vitro Techniques 11%
70. Cardiovascular Diseases 11%
71. Activating Transcription Factor 3 11%
72. Phosphorylation 10%
73. Diabetic Nephropathies 10%
74. MicroRNAs 10%
75. Insulin Resistance 10%
76. Human Influenza 10%
77. Case-Control Studies 10%
78. Creatinine 10%
79. Renal Cell Carcinoma 10%
80. Retrospective Studies 10%
81. tetramethylpyrazine 10%
82. National Health Programs 10%
83. Mesangial Cells 10%
84. Blood Pressure 10%
85. Smooth Muscle Myocytes 10%
86. Gentamicins 10%
87. Atrial Fibrillation 10%
88. Cell Line 10%
89. Growth 10%
90. Urinary Bladder 10%
91. Neoplasm Metastasis 9%
92. Cell Proliferation 9%
93. Psidium 9%
94. Epoprostenol 9%
95. Non-Small Cell Lung Carcinoma 9%
96. Testosterone 9%
97. Endoplasmic Reticulum Stress 9%
98. Antioxidants 9%
99. Fibroblasts 9%
100. Incidence 9%